Pharming (PHAR) Return on Capital Employed (2021 - 2026)
Pharming's (PHAR) quarterly Return on Capital Employed came in at 4.77% in Q2 2026, up 332563768.0% YoY from N/an in Q2 2025, and down 17.03% on a QoQ basis from 5.75% in Q1 2026.
Pharming (PHAR) Return on Capital Employed (2021 - 2026) Analysis & Trends
Pharming (PHAR) has 6 years of Return on Capital Employed data on file, last reported at 4.77% in Q2 2026.
- Quarterly Return on Capital Employed rose 332563768.0% year-over-year to 4.77% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 4.77% (up 332563768.0% YoY) and the FY2025 annual result came in at 7.73%, up 1014.0% from the prior year.
- Return on Capital Employed declined to 4.77% in Q2 2026, from 5.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1202757.46% in Q3 2024 to a low of 4111705.26% in Q3 2025.
- A 5-year average of 721955.91% and a median of 0.02% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 531446272 bps — and 2026, when it soared 345629450 bps.
- Tracing PHAR's Return on Capital Employed over 5 years: stood at 0.03% in 2022, then tumbled by 18332 bps to 5.41% in 2023, then sank by 61046782 bps to 3304351.36% in 2024, then jumped by 100 bps to 5.93% in 2025, then declined by 19 bps to 4.77% in 2026.
- The last three Return on Capital Employed figures came in at 4.77% (Q2 2026), 5.75% (Q1 2026), and 5.93% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 4.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77% |
| Mar 31, 2026 | 5.75% |
| Dec 31, 2025 | 5.93% |
| Sep 30, 2025 | -4,111,705.26% |
| Jun 30, 2025 | -3,325,632.91% |
| Mar 31, 2025 | -3,456,288.75% |
| Dec 31, 2024 | -3,304,351.36% |
| Sep 30, 2024 | 1,202,757.46% |
| Jun 30, 2024 | -4.13% |
| Mar 31, 2024 | -9.29% |
| Dec 31, 2023 | -5.41% |
| Sep 30, 2023 | 2.27% |
| Jun 30, 2023 | 3.92% |
| Mar 31, 2023 | 11.04% |
| Dec 31, 2022 | 0.03% |
| Sep 30, 2022 | 0.01% |
| Jun 30, 2022 | 1.25% |
| Mar 31, 2022 | -1.75% |
| Dec 31, 2021 | 0.42% |
| Sep 30, 2021 | 14.23% |